Abcuro Announces $155 Million Oversubscribed Series B Financing To Further Advance Autoimmune Pipeline
Amount Raised
$155 Million
Round Type
Series B
NewtonvilleBiotechnologyHealth CareTherapeuticsInvestors
Description
Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the successful close of an oversubscribed $155 million Series B financing co-led by Redmile Group and Bain Capital Life Sciences.
Quick answer
Abcuro raised $155 Million in a Series B round, dated August 17, 2023. Investors: Soleus Capital, Eurofarma, Mass General Brigham Ventures, Black Rock, Tekla Capital Management, Llc, Pontifax, New Leaf Ventures and Sanofi Ventures. Abcuro is based in Newtonville, Massachusetts, United States.
- How much did Abcuro raise?
- Abcuro raised $155 Million in a Series B round on August 17, 2023.
- Who invested in Abcuro?
- Soleus Capital, Eurofarma, Mass General Brigham Ventures, Black Rock, Tekla Capital Management, Llc, Pontifax, New Leaf Ventures and Sanofi Ventures are named as investors in this round.
- What does Abcuro do?
- Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer..
- Where is Abcuro based and how big is it?
- Abcuro is based in Newtonville, Massachusetts, United States.
- Who are the decision-makers at Abcuro?
- Fundz holds 2 contacts at Abcuro, including the Executive Officer, Director. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Abcuro that raised within 45 days of this round, from Fundz verified event records.
- Acasti raised $7.5M (Post-IPO Equity) on September 26, 2023.
- Acasti raised $7.5M on September 25, 2023.
- Qihan Biotech raised an undisclosed amount (Series B) on September 23, 2023.
- DalCor Pharmaceuticals raised $80M (Series D) on September 13, 2023.
- Renibus Therapeutics raised an undisclosed amount (Series B) on September 12, 2023.
- Grit Biotechnology raised $60M (Series B) on September 8, 2023.
Who to call at Abcuro, and when
A new round usually means Abcuro is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Abcuro raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Abcuro, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Abcuro. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Abcuro raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAbcuro raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.